News

Drug heals broken heart
Enlarge image

ResearchUK

Drug heals broken heart

28.05.2013 - Researchers have presented new preclinical data on a mitochondria-protecting drug that could reduce tissue damage following heart attacks.

During a heart attack, the major vessels that supply the heart with blood become blocked, preventing oxygen from reaching an area of the heart tissue. When the patient reaches hospital, doctors remove the blockage using medicines or surgery and restore blood flow to the heart, however in almost 100% of cases, tissue damage occurs when blood flow is restored. 

A team headed by Michael Murphy has now unravelled how the novel mitochondria-selective S-nitrosating agent, MitoSNO, protects the heart from oxidative damage, which occurs when blood flow is restored after infarction (Nature Medicine ). In a mouse model, they found that S-nitrosation of the mitochondrial complex I slows the reactivation of mitochondria during the crucial first minutes of the reperfusion of ischemic tissue, thereby decreasing ROS production, oxidative damage and tissue necrosis. 

MitoSNO works by briefly ‘switching off’ the mitochondria in the first few minutes after blood flow is returned to prevent a build-up of free radicals that can kill heart cells through apoptosis. To achieve this, MitoSNO is designed to accumulate inside heart mitochondria rapidly after its injection into the blood. In detail, MitoSNO1-induced production of nitric oxide radicals reversibly inhibits respiration at cytochrome c oxidase and increased extracellular oxygen concentration under hypoxic conditions. 

Dr Mike Murphy from the MRC Mitochondrial Biology Unit, who led the study, said: “When cells are starved of oxygen for any length of time, they begin to shut down. When blood rushes back, the mitochondria go into over-drive, churning out free radicals that cause the cells to die. MitoSNO effectively flicks a switch in the mitochondria, slowing down reactivation during those critical first minutes when blood flow returns and protecting the heart tissue from further damage. The researchers now hope to secure funding to test their new compound in early human studies.  

 © eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-02/drug-heals-broken-heart.html

BusinessUKSwitzerland

29.07.2015 Newly founded Mereo BioPharma has acquired three mid-stage clinical assets from Novartis. In turn, the Swiss pharma concern will hold a stake in the UK company. Other investors are also on board.

M&AIreland

28.07.2015 Irish Allergan is bolstering its product pipeline with a takeover of CNS specialist Naurex. At the same time, the company is divesting its global generics business to Teva.

Public marketGermanyFranceBelgiumFinlandDenmarkUK

24.07.2015 Biotech companies across Europe continue to raise cash on the public markets, generating €3bn in total financing proceedings in the first half of 2015. Compared to 2014, this is almost twice as much.

FinanceFrance

23.07.2015 US money keeps flowing into Europe's biotechs. As the race for the peanut allergy market heats up, NASDAQ listed French biotech DBV has announced the successful closing of US$281m (€256m) share offering for its allergy products.

BioplasticsFrance

21.07.2015 French biotech Deinove has launched a R&D programme to produce the versatile chemical intermediate muconic acid by using a designer variant of the Deinococcus bacteria.

BusinessFrance

16.07.2015 Sanofi has announced plans to restructure its business in five standalone global business units starting in January 2016. The goal is to promote growth and help the company launch a catalogue of new drugs over the next five years.

R&DUK

15.07.2015 GlaxoSmithKline (GSK) has become the first drugmaker to join the Francis Crick Institute. It is a consortium made up of six scientific and academic institutes to conduct research and drug development in the UK. The new institute is set to become a world-leading centre of biomedical research and innovation.

FundingUK

13.07.2015 UK drug developer ReNeuron has pulled in £68.4m (€96m) for its cell therapy pipeline for stroke and blindness treatments. Biotech guru Neil Woodford increases his fund’s stake in ReNeuron.

BusinessSweden

10.07.2015 Karolinska Development has slashed the reported value of its portfolio by almost half by revising its valuation model for early stage companies and divesting its shares in pain med maker Pharmanest.

M&AIreland

08.07.2015 Horizon Pharma plc. has set its sights on US-American speciality pharma company Depomed Inc. After getting nowhere with the rival’s board, Horizon has now launched a US$3bn hostile bid for the pain and CNS specialist.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • DIAMYD MEDICAL -B- (S)9.85 SEK15.20%
  • ZEALAND PHARMA (DK)158.00 DKK12.86%
  • ERYTECH PHARMA (F)36.51 EUR6.13%

FLOP

  • FLAMEL TECHNOLOGIES (F)23.00 USD-10.47%
  • ZELTIA (E)3.69 EUR-8.44%
  • WILEX (D)3.28 EUR-6.29%

TOP

  • IXICO (UK)35.00 GBP55.6%
  • DBV TECHNOLOGIES (F)79.73 EUR53.7%
  • ZEALAND PHARMA (DK)158.00 DKK43.0%

FLOP

  • BIOTEST (D)25.73 EUR-63.2%
  • CHRONTECH PHARMA (S)0.01 SEK-50.0%
  • BIOTECH PHARMACON (N)9.47 NOK-44.9%

TOP

  • ADOCIA (F)90.49 EUR556.2%
  • FORMYCON (D)28.68 EUR318.7%
  • DBV TECHNOLOGIES (F)79.73 EUR305.5%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-88.9%
  • NEOVACS (F)1.02 EUR-70.9%
  • NEUROVIVE PHARMACEUTICAL AB (S)22.00 SEK-68.6%

No liability assumed, Date: 29.07.2015